Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
AssigneeDuke University
InventorsJoel H. Collier, Yaoying Wu, Vincent P. Conticello
Life of this patent
Estimating the term…
Abstract
Embodiments are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.
Claims66
An immunogenic composition comprising a peptide fibril coupled to a plurality of antigens, wherein the peptide fibril comprises a plurality of alpha helices.
The composition of any one of the previous claims, wherein the self-assembling peptide is conjugated to an antigen.
The composition of any one of the previous claims, wherein each self-assembling peptide is conjugated to an antigen.
The composition of any one of the previous claims, wherein the antigen is covalently coupled to the self-assembling peptide.
The composition of any one of the previous claims, wherein the antigen is covalently coupled to a terminus of the self-assembling peptide.
The composition of any one of the previous claims, wherein the antigens are exposed on the exterior surface of the peptide fibril.
The composition of any one of the previous claims, wherein the antigen is selected from a small molecule, nucleotide, polynucleotide, peptide, polypeptide, protein, lipid, carbohydrate, and a combination thereof.
The composition of any one of the above claims, wherein the peptide fibril comprises at least two different antigens.
The composition of any one of the above claims, wherein the peptide fibril comprises self-assembling peptides not conjugated to the antigen and self-assembling peptides conjugated to the antigen, and wherein the peptide fibril comprises at least two different antigens.
The composition of any one of the above claims, wherein the plurality of antigens comprises a B cell epitope, or T cell epitope, or a combination thereof.
The composition of any one of the above claims, wherein the peptide fibril is non-toxic.
The composition of any one of claims 1-222, wherein the self-assembling peptide comprises an amino acid sequence of ZnbXXXbZm (SEQ ID NO:
- 5), wherein b is independently any positively charged amino acid, Z is independently any amino acid, X is independently any amino acid, n is an integer from 0 to 20, and m is an integer from 0 to 20.
The composition of any one of the above claims, wherein the self-assembling peptide comprises a glutamine at the C-terminus.
The composition of any one of the above claims, wherein the self-assembling peptide comprises a glutamine at the N-terminus.
The composition of any one of the previous claims, wherein the self-assembling peptide further comprises a linker between the antigen and self-assembling peptide.
The composition of any one of the previous claims, wherein the peptide fibril is at least 250 nanometers in length.
The composition of any one of the previous claims, wherein the composition further comprises an adjuvant.
The composition of any one of the previous claims, wherein the composition does not further comprise an adjuvant.
The composition of any one of the previous claims, wherein the peptide fibril is an adjuvant.
The composition of any one of the previous claims, wherein the self-assembling peptide is synthesized by a solid phase peptide synthesis.
Dependencies are inferred from the claim text.